2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.
Over the past several years, 7 trials have examined erlotinib and gefitinib compared with chemotherapy for the treatment of lung cancer patients with EGFR mutations. These studies have all shown progression-free survival (PFS) and objective response benefit with the EGFR inhibitors.
Sequist says the PFS data from LUX-Lung 3 and LUX-Lung 6 led to the approval of afatinib in many countries. Identical results were seen between the two studies — there was no survival advantage between afatinib and chemotherapy, though patients with different EGFR mutations experienced varying degrees of benefit.
<<<
View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology